Despite concerns about increasing competition, Regeneron Pharmaceuticals, Inc. is expanding its footprints in bispecific antibodies and in gene therapy – and management indicated the firm may be on the lookout for additional development deals.
The Tarrytown, NY-based drug maker announced its third quarter earnings on 2 November, reporting that sales increased 15% year-over-year to $3
Key Takeaways
-
Regeneron announced its third quarter 2023 earnings, with sales up 15% year-over-year.
-
The original version of Eylea posted declining sales, but the company pointed to hopeful signs for the newly approved high-dose version
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?